Leukotrienes modulate cytokine release from dendritic cells
- 28 September 2005
- journal article
- Published by Wiley in Immunology
- Vol. 116 (4) , 418-428
- https://doi.org/10.1111/j.1365-2567.2005.02241.x
Abstract
Leukotriene B(4) (LTB(4)) and cysteinyl leukotrienes (CysLTs) are known as potent mediators of inflammation, whereas their role in the regulation of adaptive immunity remains poorly characterized. Dendritic cells (DCs) are specialized antigen-presenting cells, uniquely capable to initiate primary immune responses. We have found that zymosan, but not lipopolysaccharide (LPS) stimulates murine bone marrow-derived dendritic cells (BM-DCs) to produce large amounts of CysLTs and LTB(4) from endogenous substrates. A selective inhibitor of leukotriene synthesis MK886 as well as an antagonist of the high affinity LTB(4) receptor (BLT(1)) U-75302 slightly inhibited zymosan-, but not LPS-stimulated interleukin (IL)-10 release from BM-DCs. In contrast, U-75302 increased zymosan-stimulated release of IL-12 p40 by approximately 23%. Pre-treatment with transforming growth factor-beta1 enhanced both stimulated leukotriene synthesis and the inhibitory effect of U-75302 and MK886 on IL-10 release from DCs. Consistent with the effects of leukotriene antagonists, exogenous LTB(4) enhanced LPS-stimulated IL-10 release by approximately 39% and inhibited IL-12 p40 release by approximately 22%. Both effects were mediated by the BLT(1) receptor. Ligands of the high affinity CysLTs receptor (CysLT(1)), MK-571 and LTD(4) had little or no effect on cytokine release. Agonists of the nuclear LTB(4) receptor peroxisome proliferator-activated receptor-alpha, 8(S)-hydroxyeicosatetraenoic acid and 5,8,11,14-eicosatetraynoic acid, inhibited release of both IL-12 p40 and IL-10. Our results indicate that both autocrine and paracrine leukotrienes may modulate cytokine release from DCs, in a manner that is consistent with previously reported T helper 2-polarizing effects of leukotrienes.Keywords
This publication has 49 references indexed in Scilit:
- Pranlukast Inhibits NF-κB Activation and MUC2 Gene Expression in Cultured Human Epithelial CellsPharmacology, 2005
- Targeted Gene Disruption Reveals the Role of Cysteinyl Leukotriene 1 Receptor in the Enhanced Vascular Permeability of Mice Undergoing Acute Inflammatory ResponsesJournal of Biological Chemistry, 2002
- Hydroxyeicosanoids Bind to and Activate the Low Affinity Leukotriene B4 Receptor, BLT2Journal of Biological Chemistry, 2001
- Immunosuppressive Effect of Leukotriene B4 Receptor Antagonist in VitroBiochemical and Biophysical Research Communications, 1999
- Transforming Growth Factor β1, in the Presence of Granulocyte/Macrophage Colony-stimulating Factor and Interleukin 4, Induces Differentiation of Human Peripheral Blood Monocytes into Dendritic Langerhans CellsThe Journal of Experimental Medicine, 1998
- Translocation and Leukotriene Synthetic Capacity of Nuclear 5-Lipoxygenase in Rat Basophilic Leukemia Cells and Alveolar MacrophagesPublished by Elsevier ,1995
- Isoleukotrienes Are Biologically Active Free Radical Products of Lipid PeroxidationPublished by Elsevier ,1995
- Generation of large numbers of dendritic cells from mouse bone marrow cultures supplemented with granulocyte/macrophage colony-stimulating factor.The Journal of Experimental Medicine, 1992
- Leukotrienes do not regulate interleukin 1 production by activated macrophagesBiochemical and Biophysical Research Communications, 1990
- Effect of AA‐861, a 5‐Lipoxygenase Inhibitor, on Leukotriene Synthesis in Human Polymorphonuclear Leukocytes and on Cyclooxygenase and 12‐Lipoxygenase Activities in Human PlateletsAllergy, 1986